TAXIS Pharmaceuticals, Inc. – Antimicrobial Pipeline

• Focused on Discovery & Development of Novel Antibiotics to address Growing Threat to Societal Health of MDR Pathogens
  – Licensed Rutgers University technology: Broad patent portfolio
  – 10 employees; 3500 sq.ft. Chemistry & Biology laboratories, Monmouth Junction, NJ, USA
  – NCEs and Enhancement of existing classes; Gram(+) and Gram (-) drug candidates

• Anti-MRSA (+StrepA) Drug Development – Lead Candidate: TXA709
  – 91% Oral bioavailability; Synergistic w/beta-lactams; No cross resistance w/Marketed Drugs
  – FDA granted TXA709 QIDP designation; Completing GMP/GLP preclinical toxicology in 2017
  – Target markets: inpatient IV w/oral stepdown for sepsis and outpatient oral for cSSSI
  – 7Kg supply of GMP material in hand; progressing toward Phase 1, FIH trials by 1Q,’18

• Psuedomonas, Klebsiella, E. Coli & Acinetobacter Drug Development
  – Efflux Pump Inhibition (EPI): 3 distinct Classes of Novel compounds
    Resurrect Activity of Generic Antibiotics
    • Durable, validated in vivo efficacy in P. aeruginosa murine septicemia model of infection
    • In vitro potency enhancement up to 256X; in presence of EPIs, 1-log reduction in adjuvants’ FOR
    • Broad patent estate including 2 US, 2 PCT and 4 provisional applications
    • Characterization of PK & Safety Pharmacology, 3Q’17; Lead Optimization and Identification by 2Q, ’18
    • MOA documented as Efflux Pump Inhibition; not associated w/ membrane disruption
    • Multiple publication submissions to high profile journals & NIH/NIAID grant applications in 2Q/3Q, ’17
  – Enhancing Legacy Antibiotic Technologies
    • Primary Target Market: IV therapeutics for VAP caused by P. aeruginosa & A. baumannii
    • Promising novel approach to discovery in under-exploited Gram(-) class w/ freedom to operate
    • Excluding beta-lactams and fluoroquinolones

• Influenza A Endonuclease Inhibitors – Early Stage